clevercast
{"PLE04":{"id":"WdekGw","strictid":"PLE04","name":"PLE04","description":"","account_id":"2bK6rw","ts":0},"PLE05":{"id":"W9mpyj","strictid":"PLE05","name":"PLE05 Closing Ceremony + Concert","description":"","account_id":"2bK6rw","ts":1638855000},"SAT09":{"id":"VvyakX","strictid":"SAT09","name":"SAT09","description":"","account_id":"2bK6rw","ts":1638889200},"SPI07":{"id":"WwGDRw","strictid":"SPI07","name":"SPI07","description":"","account_id":"2bK6rw","ts":1638874920},"SCS14":{"id":"2avEmE","strictid":"SCS14","name":"SCS14","description":"","account_id":"2bK6rw","ts":1638874920},"SCS13":{"id":"A6nmKN","strictid":"SCS13","name":"SCS13","description":"","account_id":"2bK6rw","ts":1638874920},"KEY09":{"id":"Wlqkxg","strictid":"KEY09","name":"KEY09","description":"","account_id":"2bK6rw","ts":1638874920},"KEY06":{"id":"AGZbol","strictid":"KEY06","name":"KEY06","description":"","account_id":"2bK6rw","ts":1638873120},"KEY01":{"id":"AR1vr7","strictid":"KEY01","name":"KEY01","description":"","account_id":"2bK6rw","ts":1638871320},"PLE03":{"id":"VyOE09","strictid":"PLE03","name":"PLE03","description":"","account_id":"2bK6rw","ts":1638867600},"WEB05":{"id":"AKYxLw","strictid":"WEB05","name":"WEB05","description":"","account_id":"2bK6rw","ts":1638824520},"WEB04":{"id":"V316Xb","strictid":"WEB04","name":"WEB04","description":"","account_id":"2bK6rw","ts":1638817320},"KEY05":{"id":"WNKJlG","strictid":"KEY05","name":"KEY05","description":"","account_id":"2bK6rw","ts":1638811920},"SPI06":{"id":"VBXxdo","strictid":"SPI06","name":"SPI06","description":"","account_id":"2bK6rw","ts":0},"SCS12":{"id":"VYeD58","strictid":"SCS12","name":"SCS12","description":"","account_id":"2bK6rw","ts":1638810120},"SCS10":{"id":"VDrPkz","strictid":"SCS10","name":"SCS10","description":"","account_id":"2bK6rw","ts":1638810120},"KEY03":{"id":"W9mpEj","strictid":"KEY03","name":"KEY03","description":"","account_id":"2bK6rw","ts":1638810120},"SAT08":{"id":"VvyaNX","strictid":"SAT08","name":"SAT08","description":"","account_id":"2bK6rw","ts":0},"SAT07":{"id":"WwGD3w","strictid":"SAT07","name":"SAT07","description":"","account_id":"2bK6rw","ts":0},"SPI05":{"id":"VznBKn","strictid":"SPI05","name":"SPI05","description":"","account_id":"2bK6rw","ts":1638788520},"SCS11":{"id":"ApYQ5M","strictid":"SCS11","name":"SCS11","description":"","account_id":"2bK6rw","ts":1638788520},"SCS09":{"id":"2MnrZe","strictid":"SCS09","name":"SCS09","description":"","account_id":"2bK6rw","ts":1638788520},"SPI04":{"id":"Wlqkpg","strictid":"SPI04","name":"SPI04","description":"","account_id":"2bK6rw","ts":1638781320},"SCS08":{"id":"ALoQw5","strictid":"SCS08","name":"SCS08","description":"","account_id":"2bK6rw","ts":1638781320},"SCS07":{"id":"AGZbgl","strictid":"SCS07","name":"SCS07","description":"","account_id":"2bK6rw","ts":1638781320},"WEB03":{"id":"WokLe9","strictid":"WEB03","name":"WEB03","description":"","account_id":"2bK6rw","ts":1638738120},"SAT04":{"id":"Ak6yrj","strictid":"SAT04","name":"SAT04","description":"","account_id":"2bK6rw","ts":0},"SAT06":{"id":"WdekLm","strictid":"SAT06","name":"SAT06","description":"","account_id":"2bK6rw","ts":0},"KEY08":{"id":"WNKJwG","strictid":"KEY08","name":"KEY08","description":"","account_id":"2bK6rw","ts":1638716520},"KEY10":{"id":"2bzB4G","strictid":"KEY10","name":"KEY10","description":"","account_id":"2bK6rw","ts":0},"SCS04":{"id":"VPxn5l","strictid":"SCS04","name":"SCS04","description":"","account_id":"2bK6rw","ts":1638716520},"SCS03":{"id":"WdekLP","strictid":"SCS03","name":"SCS03","description":"","account_id":"2bK6rw","ts":1638716520},"SPI02":{"id":"21a6D6","strictid":"SPI02","name":"SPI02","description":"Societal impact of influenza and COVID-19","account_id":"2bK6rw","ts":1638702120},"KEY02":{"id":"VznBQJ","strictid":"KEY02","name":"KEY02","description":"","account_id":"2bK6rw","ts":1638702000},"SCS06":{"id":"ApYQJq","strictid":"SCS06","name":"SCS06","description":"Innate and adaptive immunity towards influenza, RSV disease and COVID-19","account_id":"2bK6rw","ts":1638702120},"SPI01":{"id":"AZzDlk","strictid":"SPI01","name":"SPI01","description":"Why influenza is a priority for policy makers","account_id":"2bK6rw","ts":1638694920},"SCS02":{"id":"Wj0kJZ","strictid":"SCS02","name":"SCS02","description":"Virus structure and replication in influenza virus, RSV and SARS-CoV-2; latest developments in influenza virus, SARS-CoV-2 and RSV molecular virology","account_id":"2bK6rw","ts":1638694920},"SCS01":{"id":"24amLe","strictid":"SCS01","name":"SCS01","description":"Epidemiology, surveillance and modelling of influenza, RSV disease and COVID-19, including virus evolution and strain selection","account_id":"2bK6rw","ts":1638694920},"WEB02":{"id":"Ak6yJr","strictid":"WEB02","name":"WEB02","description":"Childhood Influenza vaccination and treatment in a COVID-19 era","account_id":"2bK6rw","ts":1638651720},"OPN01":{"id":"WqYk9o","strictid":"OPN01","name":"OPN01","description":"Opening Ceremony\n","account_id":"2bK6rw","ts":1638637200},"KEY04":{"id":"27y68N","strictid":"KEY04","name":"KEY04","description":"COVID coagulopathy in comparison to influenza and pneumococci sepsis","account_id":"2bK6rw","ts":1638694920},"PER01":{"id":"2bzBJX","strictid":"PER01","name":"Permanent Livestream","description":"","account_id":"2bK6rw","ts":0},"SAT03":{"id":"VBXxaB","strictid":"SAT03","name":"SAT03","description":"","account_id":"2bK6rw","ts":1638630000},"SAT02":{"id":"VYeDlQ","strictid":"SAT02","name":"SAT02","description":"INFLUENZA AND COVID-19 Burden of Disease and Prospects for Vaccination","account_id":"2bK6rw","ts":1638622800},"SAT01":{"id":"VBXxPX","strictid":"SAT01","name":"SAT01 ","description":"Post-COVID lockdown era: what are we facing?","account_id":"2bK6rw","ts":1638615600},"WEB01":{"id":"VYeD8w","strictid":"WEB01","name":"WEB01","description":"Vaccination in a COVID-19 era","account_id":"2bK6rw","ts":1638644520},"SAT05":{"id":"ApYQNa","strictid":"SAT05","name":"SAT05","description":"Will be streamed by Roche, not from studio Antwerp, BE","account_id":"2bK6rw","ts":1638709200}}
clevercast items
{"LAN01":{"id":"WEBElL","strictid":"LAN01","name":"Lange testtrailer","description":"","account_id":"2bK6rw","chapters":[]},"TES01":{"id":"W9Jpob","strictid":"TES01","name":"Testtrailer","description":"Test trailer for scheduling Pseudo Live Events","account_id":"2bK6rw","chapters":[]}}
Sat 4 Dec
Saturday
4
December

Saturday 4 December, 12:00 - 13:45 CET

Satellite Symposium organised by Janssen: Post-COVID lockdown era: what are we facing?SAT01

Live
Time:

Saturday 4 December, 12:00 - 13:45 CET

Track:

Satellite sessions


Chairs:
Stefan Scholten, Praxis Hohenstaufenring
Carlo Federico Perno, UniCamillus International Medical University Rome

Programme:

1.     Opening remarks and introduction

Dr. med. Stefan Scholten & Professor Carlo Federico Perno

2.     COVID-19 examined: Expansion of the virus & variants

Dr. Federico Garcia, Head, Department of Microbiology, University Hospital San Cecilio

3.     The tango of interactions between respiratory viruses and the immune system: What is the result?

Professor Andrea Cossarizza, Full Professor of Pathology and Immunology, University of Modena, School of Medicine

4.     Panel discussion and live Q&A

Dr. med. Stefan Scholten, Professor Carlo Federico Perno, Dr. Federico Garcia & Professor Andrea Cossarizza

 


Programme:
  1. COVID-19 examined: Expansion of the virus & variants

    Federico Garcia, Hospital Universitario San Cecilio, Spain
  2. The tango of interactions between respiratory viruses and the immune system: What is the result?

    Andrea Cossarriza, University of Modena, Italy

Saturday 4 December, 14:00 - 15:45 CET

Satellite Symposium organised by Sanofi Pasteur: INFLUENZA AND COVID-19 Burden of Disease and Prospects for VaccinationSAT02

Live
Time:

Saturday 4 December, 14:00 - 15:45 CET

Track:

Satellite sessions


Chair:
Ursula Kunze, Medical University Vienna

Programme:
  1. Introduction and symposium opener

    Ursula Kunze, Medical University Vienna, Austria
  2. The burden of influenza and COVID-19

    Melissa K. Andrew, Dalhousie University, Canada
  3. Towards increased awareness on the evidence quality and data robustness for vaccines efficacy and effectiveness: Recent STIKO’ GRADE analysis for newer influenza vaccines in Germany

    Jörg Schelling, University Hospital of Ludwig-Maximilians - University Munich, Germany
  4. Recombinant Quadrivalent Influenza Vaccine for those 18 years of age and older

    Jaime Jesus Perez Martín, Dirección General de Salud Pública y Adicciones, Spain
  5. Lessons learnt from influenza vaccination experience to COVID-19 vaccines development

    Béhazine Combadière, Sorbonne University, France
  6. Q&A Live panel of all presenters, facilitated by the Chair

    Ursula Kunze, Medical University Vienna, Austria

Saturday 4 December, 16:00 - 17:45 CET

Satellite Symposium funded and organised by Seqirus: Influenza during COVID-19 and beyond: Challenges, Technologies and StrategiesSAT03

Live
Time:

Saturday 4 December, 16:00 - 17:45 CET

Track:

Satellite sessions


Chair:
David Salisbury, David Salisbury Consulting Limited

Programme:
  1. Perspectives from the COVID-19/influenza interface

    David Salisbury, David Salisbury Consulting Limited, United Kingdom
  2. The challenges of seasonal influenza and SARS-CoV-2 co-circulation

    Andrea Orsi, University of Genoa, Italy
  3. Differentiated vaccines for seasonal influenza prevention: Real-world evidence

    Tino Schwarz, Klinikum Würzburg Mitte, Germany
  4. Pandemic preparedness: Applying lessons from COVID-19 to influenza

    Ab Osterhaus, TiHo, Hannover, Germany
  5. Panel and audience discussion

    David Salisbury, David Salisbury Consulting Limited, United Kingdom
  6. Close

    David Salisbury, David Salisbury Consulting Limited, United Kingdom
Sun 5 Dec
Sunday
5
December

Sunday 5 December, 14:00 - 15:30 CET

Satellite symposium organised by Roche: Impact of influenza antivirals in the post–COVID-19 era and preparing for the next pandemicSAT05

Live
Time:

Sunday 5 December, 14:00 - 15:30 CET

Track:

Satellite sessions


Chair:
Tristan Clark, University of Southampton

This is a non-promotional meeting that is intended for healthcare professionals outside the United States of America


Programme:
  1. Welcome and introduction

    Tristan Clark, University of Southampton, United Kingdom
  2. Impact of COVID-19 on the clinical management of influenza patients

    Tristan Clark, University of Southampton, United Kingdom
  3. Role of antivirals in onwards transmission and prophylaxis of influenza

    Nelson Lee, University of Toronto, Canada
  4. Role of antivirals in pandemic preparedness

    Ben Cowling, The University of Hong Kong, Hong Kong S.A.R.
  5. Panel discussion: all panellists

    Tristan Clark, University of Southampton, United Kingdom
  6. Summary and closing remarks

    Tristan Clark, University of Southampton, United Kingdom
  7. Meet-the-expert session with Tristan Clark, Ben Cowling and Nelson Lee

    Tristan Clark, University of Southampton, United Kingdom

Sunday 5 December, 18:00 - 19:30 CET

Satellite Symposium organised by AstraZeneca: Tackling COVID-19: Exploring the prophylaxis toolkitSAT06

Live
Time:

Sunday 5 December, 18:00 - 19:30 CET

Track:

Satellite sessions


Chair:
Flor Munoz, Baylor College of Medicine

This non-promotional scientific exchange symposium has been organised and funded by AstraZeneca. 

Any information presented regarding vaccines, prophylaxis or treatment options for COVID-19 will be fair and balanced.

Veeva ID: XL-2357; Date of preparation: October 2021


Programme:
  1. Welcome & Introduction: where are we in the fight against COVID-19?

    Flor Munoz, Baylor College of Medicine, United States of America
  2. Future outlooks: strategies for COVID-19 prevention

    Hugh Montgomery, University College London / Astra Zeneca, United Kingdom
  3. Who is still at risk from COVID-19 in the post-vaccination world?

    Mona Al-Ahmad, Al-Rashed Allergy Center, Kuwait
  4. Panel discussion

    Flor Munoz, Baylor College of Medicine, United States of America

Sunday 5 December, 20:00 - 21:45 CET

Satellite Symposium organised by Pfizer: Evolving the Science of mRNA Vaccines: Helping to Protect Against COVID‐19 TodaySAT04

Live
Time:

Sunday 5 December, 20:00 - 21:45 CET

Track:

Satellite sessions


Chair:
Shanti Pather, BioNTech

Programme:
  1. Welcome and Introductions

    Shanti Pather, BioNTech, United Kingdom
  2. Evaluating the Evidence Supporting a Booster Dose of BNT162b2 COVID‐19 mRNA Vaccine

    Romina Quercia, Pfizer, United Kingdom
  3. Clinical Development of BNT162b2 COVID‐19 mRNA Vaccine in Adolescents

    David Weber, UNC School of Medicine, United States of America
  4. Faculty Panel Discussion and Q&A with Shanti Pather, Romina Quercia and David Weber

    Shanti Pather, BioNTech, United Kingdom
  5. Closing Remarks

    Shanti Pather, BioNTech, United Kingdom
Mon 6 Dec
Monday
6
December

Monday 6 December, 14:00 - 15:00 CET

Satellite Symposium organised by Roche: Advancing COVID-19 treatment: current and future perspectives on antiviralsSAT07

Live
Time:

Monday 6 December, 14:00 - 15:00 CET

Track:

Satellite sessions


Chair:
Frederick G. Hayden, University of Virginia

This is a non-promotional meeting that is intended for healthcare professionals outside the United States of America


Programme:
  1. Welcome and introduction

    Frederick G. Hayden, University of Virginia, United States of America
  2. Neutralising antibodies for the treatment and prevention of COVID-19

    Zain Chagla, McMaster University, Canada
  3. Data in context: the role of antivirals in the future of COVID-19 care

    Alex Soriano, Hospital Clínic of Barcelona, Spain
  4. Roundtable discussion

    Frederick G. Hayden, University of Virginia, United States of America
  5. Summary and closing remarks

    Frederick G. Hayden, University of Virginia, United States of America

Monday 6 December, 16:00 - 17:30 CET

Satellite Symposium organised by Sabin Vaccine Institute’s Influenzer Intiative: “The Influenza Vaccines R&D Roadmap: Framework for a Flu-Free Future”SAT08

Live
Time:

Monday 6 December, 16:00 - 17:30 CET

Track:

Satellite sessions


Welcome & Introduction of the IVR Initiative 

Stacey Knobler, Vice President of Vaccine Innovation, Sabin Vaccine Institute

Mike Osterholm, Director, Center for Infectious Disease Research and Policy (CIDRAP)

Video Screening: “Road to a Flu-Free Future”

Panel Discussion

Cherry Kang, Professor,The Wellcome Trust Research Laboratory, , Christian Medical College Vellore

Patrick Tippoo, Head of Science and Innovation, Biovac; Executive Director and founding member, African Vaccine Manufacturing Initiative (AVMI)

Joe Bresee, Director, Respiratory Virus Prevention Programs, Center for Vaccine Equity, Task Force for Global Health

Ethan Settembre, Vice President, Research at Seqirus

Charlie Weller, Head of Prevention, Research Programmes, Wellcome Trust

John Lim, Executive Director, Centre of Regulatory Excellence, Duke-NUS Medical School Singapore; Chairman, Consortium for Clinical Research & Innovation Singapore           

Rajeev Venkayya, President, Global Vaccine Business Unit, Takeda Pharmaceutical

Audience Question & Answer

Closing Comments & Feature Film Preview

Tue 7 Dec
Tuesday
7
December

Tuesday 7 December, 14:00 - 15:45 CET

Satellite Symposium organised by Janssen: Shining light on the spectrum of RSV disease burden in adultsSAT09

Live
Time:

Tuesday 7 December, 14:00 - 15:45 CET

Track:

Satellite sessions


Chair:
Peter Openshaw, Imperial College London

Welcome and introduction

Peter Openshaw, Imperial College London, UK

The impact of COVID on RSV circulation

John-Sebastian Eden, Westmead Hospital, New South Wales, Australia

John-Sebastian Eden/Peter Openshaw

Adults at risk of severe RSV: The burden of RSV in adults with underlying comorbidities

Angela Branche, University of Rochester, US

Angela Branche/Peter Openshaw

RSV in older adults: An increasing problem with an aging population

Dexter Wiseman, Imperial College London, UK

Dexter Wiseman/Peter Openshaw

Interactive panel Q&A

All

Summary and meeting close

Peter Openshaw

  FILTER